Neurenati

Montreal, Canada Founded: 2020 • Age: 6 yrs
Biotech company focused on developing therapies for rare diseases, with a current focus on Hirschsprung disease

About Neurenati

Neurenati is a company based in Montreal (Canada) founded in 2020.. Neurenati has raised $2.9 million across 2 funding rounds from investors including Invest Quebec. Neurenati offers products and services including NEU-001. Neurenati operates in a competitive market with competitors including AllStripes, Zenas BioPharma, Prime Global, CTI Clinical Trial and Atlantic Research Group, among others.

  • Headquarter Montreal, Canada
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Neurenati Therapeutics
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $2.9 M (USD)

    in 2 rounds

  • Latest Funding Round
    $1.7 M (USD), Seed

    Apr 18, 2024

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Neurenati

Neurenati offers a comprehensive portfolio of products and services, including NEU-001. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Enema-based treatment to regenerate enteric nervous system for Hirschsprung's disease.

People of Neurenati
Headcount 1-10
Employee Profiles 2
Employee Profiles
People
Maxime Ranger
Chief Executive Officer
People
Christophe Mellon
Vice-president CMC

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of Neurenati

Neurenati has successfully raised a total of $2.9M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.7 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Seed — $1.7M
  • First Round

    (29 Feb 2024)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2024 Amount Seed - Neurenati Valuation

investors

Feb, 2024 Amount Seed - Neurenati Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Neurenati

Neurenati has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Invest Quebec. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Business guidance for corporate companies and startups
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Neurenati

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Neurenati

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Neurenati Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Neurenati

Neurenati operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AllStripes, Zenas BioPharma, Prime Global, CTI Clinical Trial and Atlantic Research Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of information to patients and communities with the medical data for rare diseases
domain founded_year HQ Location
Clinical development services for autoimmune and rare diseases are provided.
domain founded_year HQ Location
Medical communication solutions are provided for healthcare professionals.
domain founded_year HQ Location
Provides clinical trials, consulting, and regulatory services in healthcare sectors.
domain founded_year HQ Location
Contract Research Organization for clinical trials in oncology, immunology, and neurology sectors.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Neurenati

When was Neurenati founded?

Neurenati was founded in 2020 and raised its 1st funding round 4 years after it was founded.

Where is Neurenati located?

Neurenati is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.

Who is the current CEO of Neurenati?

Maxime Ranger is the current CEO of Neurenati.

Is Neurenati a funded company?

Neurenati is a funded company, having raised a total of $2.9M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.2M, raised on Feb 29, 2024.

What does Neurenati do?

Neurenati Therapeutics was founded in 2020 in Montreal, Canada, as a biotech firm targeting rare diseases. Development efforts are centered on Hirschsprung disease through the NEU-001 therapy. A 1.2 million seed financing round was recently completed to support advancement of this program. Leadership is provided by CEO Maxime Ranger, experienced in life sciences entrepreneurship and venture capital. Operations remain based in the Canadian biotech sector.

Who are the top competitors of Neurenati?

Neurenati's top competitors include Zenas BioPharma, AllStripes and Prime Global.

What products or services does Neurenati offer?

Neurenati offers NEU-001.

Who are Neurenati's investors?

Neurenati has 1 investor. Key investors include Invest Quebec.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available